Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update
(NASDAQ:RARE), Second quarter total revenue of $166 million,Crysvita(R) revenue of $120 million and Dojolvi(R) revenue of $23 million Reaffirm 2025 Revenue Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million UX143 for osteogenesis imperfecta Phase 3 data from […]